INAVO120 Trial Insights and Inavolisib's Emerging Role in the Treatment Armamentarium
Panelists discuss how the October 2024 FDA approval of inavolisib in combination with palbociclib and fulvestrant for HR positive (HR+)/ HER2 negative (HER2-) metastatic breast cancer with a PIK3CA mutation marks a pivotal advancement in precision medicine, highlighting how agents like such as inavolisib, capivasertib, elacestrant, and alpelisib have transformed treatment approaches and expanded therapeutic options for patients.
EP: 1.Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer
EP: 2.INAVO120 Trial Insights and Inavolisib's Emerging Role in the Treatment Armamentarium
EP: 3.Precision Pathways: Targeted Therapies, Mutation-Driven Treatment Strategies
EP: 4.Biomarker Testing Best Practices for Informed Treatment Decision-Making: Med Onc and Nurse Perspectives
EP: 5.Adapting Biomarker Testing Practices as Targeted Therapies Shift to Earlier Lines of Treatment
EP: 6.Hyperglycemia Monitoring and AIC Monitoring with PI3K/AKT Pathway Inhibitors: Practical Approaches and Strategies
EP: 7.Treatment Decision-Making in PIK3CA-mut HR+/HER2- Breast Cancer: Key Tolerability Considerations
EP: 8.Strategies for Staying Informed and Coordinating Care as New Agents Emerge in HR+/HER2- Breast Cancer
EP: 9.PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment Landscape
Video content above is prompted by the following:
The treatment landscape for HR+/HER2- metastatic breast cancer continues to evolve and in October 2024, we saw the FDA approval of inavolisib in combination with palbociclib and fulvestrant for HR+ /HER2- advanced or metastatic BC breast cancer with a PIK3CA mutation. This approval marks another important advancement in precision medicine for our patients.
Can you walk us through the evolution of targeted therapies in HR+/HER2- metastatic breast cancer? How have agents like such as inavolisib, capivasertib, elacestrant, and alpelisib changed our approach to treatment?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
